Pomerantz Law Firm investigates claims on Behalf of Investors of Silverback Therapeutics, Inc - SBTX / SBBX
Pomerantz LLP is investigating claims in behalf of investors of Silverback Therapeutics Inc. ("Silverback" or "Company") (NASDAQ: SBTX). Such investors should contact Robert S. Willoughby 7980.
It is questioning whether Silverback and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
If you want to join the class action, please call here.
On October 13, 2021, Silverback announced the final announcement of its first public offering (IPO) on September 13, 2020, evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in In the abstract, while the Company's experimental therapy had a manageable safety profile, the best overall response was PR (n=1), SD (N=3), and PD (PD) (do10).
On this news, Silverback's stock price fell $4,54 per share, or 23,35%, to close at $14,90 per shares on September 13, 2021.
Pomerantz LLP has offices in New York, Chicago, Los Angeles, Paris, Tel Aviv and Newy, is recognized as one of the premier firms in the fields of corporate, securities and antitrust litigation. As a founding member of the class action bar, Abraham L. Pomerantz founded the revolving class act he was known as the dean of class class actions. Pomerantz continues in his tradition today, more than 85 years later, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has recovered a number of multimillion dollar damages awards to class members. See www.pomlaw.com.
CONTACT: Robert S. WilloughbyPomerantz LLP[email protected] 888-476-6529 ext. 7980 o'clock a day.
SOURCE Pomerantz LLP s.r.l. S.S.